Novartis acquires ADC developer Myricx Bio
UK biotech Myricx Bio has reached an agreement to be acquired by Novartis for up to $1.5 billion. The companies say the acquisition advances antibody-drug conjugate (ADC) innovation by bringing together the strengths of Novartis in oncology with Myricx Bio’s two lead ADC assets and next-generation first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform, having potential… Read More
